Developing an Australian multi-module clinical quality registry for gynaecological cancers: a protocol paper.
clinical quality registry
gynaecological cancers
gynaecological oncology
quality of care
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
27 02 2020
27 02 2020
Historique:
entrez:
1
3
2020
pubmed:
1
3
2020
medline:
14
4
2021
Statut:
epublish
Résumé
Gynaecological cancers collectively account for almost 10% of cancer diagnoses made in Australian women. The extent of variation in gynaecological cancer survival rates and treatment outcomes across Australia is not well documented. The purpose of the clinical quality registry described in this paper is to systematically monitor and improve quality of care provided to these women, and facilitate clinical process improvements to ensure better patient outcomes and greater adherence to best practice care. The registry infrastructure has been developed in conjunction alongside the inaugural ovarian, tubal and peritoneal (OTP) module, allowing for concurrent piloting of the methodology and one module. Additional tumour modules will be developed in time to cover the other gynaecological tumour types. The National Gynae-Oncology Registry (NGOR) aims to capture clinical data on all newly diagnosed cancers of the uterus, ovary, fallopian tubes, peritoneum, cervix, vulva and vagina in Australia with a view to using these data to support improved clinical care and increased adherence to 'best practice'. Data are sourced from existing clinical databases maintained by clinicians and/or hospital gynaecological cancer units. A pilot phase incorporating only OTP cancers has recently been conducted to assess the feasibility of the registry methodology and assess the support of a quality initiative of this nature among clinicians and other key stakeholders. The NGOR has received National Mutual Acceptance (NMA) ethics approval from Monash Health Human Research Ethics Committee (HREC), NMA HREC Reference Number: HREC/17/MonH/198. We also have approval from Mercy Health HREC and University of Tasmania HREC. Data will be routinely reported back to participating sites illustrating their performance against measures of agreed best practice. It is through this feedback system that the registry will support changes to quality of care and improved patient outcomes.
Identifiants
pubmed: 32111617
pii: bmjopen-2019-034579
doi: 10.1136/bmjopen-2019-034579
pmc: PMC7050311
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e034579Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Gynecol Oncol. 2012 Oct;127(1):75-82
pubmed: 22750127
Med J Aust. 2010 Sep 20;193(6):326-30
pubmed: 20854236
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Semin Surg Oncol. 2000 Jul-Aug;19(1):11-9
pubmed: 10883019
Med J Aust. 2014 Sep 1;201(5):283-8
pubmed: 25163381
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:96-107
pubmed: 27806912
Gynecol Oncol. 2019 Feb;152(2):426-433
pubmed: 30503267
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Med J Aust. 2002 Jul 1;177(1):11-6
pubmed: 12088472
Gynecol Oncol. 2007 Jun;105(3):801-12
pubmed: 17433422
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Med J Aust. 2013 Feb 18;198(3):134-5
pubmed: 23418684
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
J Ovarian Res. 2019 May 7;12(1):40
pubmed: 31064392
Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10
pubmed: 10883018
Eur J Surg Oncol. 2019 Apr;45(4):528-537
pubmed: 30337202